Literature DB >> 3391093

Significance of high HbA1 levels in normal glucose tolerance.

M Modan1, D Meytes, P Rozeman, S B Yosef, E Sehayek, N B Yosef, A Lusky, H Halkin.   

Abstract

The significance of high hemoglobin A1 (HbA1) levels (greater than or equal to 8.0%) found in 12.1% of 648 individuals with normal glucose tolerance constituting a part of a representative population sample was examined. Measurement error in HbA1 and/or glucose-tolerance levels was precluded by HbA1 remaining in the same range over 3.5 yr in 89.7% of 29 individuals with initially high and 68.1% of 22 individuals with initially low (less than 6.5%) HbA1. Rate of deterioration to glucose intolerance (6.9%) in the high group during that period resembled the rate (11.8%) in a control group (n = 279). Fasting plasma glucose significantly accounted for only 2.4% of total HbA1-population variance. No correlation of HbA1 was found with other correlates of glucose tolerance or with daily caloric intake and physical activity. A small but significant increment in HbA1 was associated with smoking (7.1 vs. 6.8%, P less than .01) and with clinically overt atherosclerosis (7.3 vs. 6.9%, P less than .01). We conclude that factors unrelated to glucose metabolism are the main determinants of HbA1 level in normal glucose tolerance and play an important role in diabetes as well. These factors have bearing on evaluation of diabetic control by HbA1 and possibly on risk for diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391093     DOI: 10.2337/diacare.11.5.422

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

Review 1.  Glycated haemoglobin in the year 2000.

Authors:  E S Kilpatrick
Journal:  J Clin Pathol       Date:  2000-05       Impact factor: 3.411

Review 2.  Type 2 diabetes mellitus and cardiovascular exercise performance.

Authors:  Judith G Regensteiner
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 3.  Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.

Authors:  Dragana Lovre; Sulay Shah; Aanu Sihota; Vivian A Fonseca
Journal:  Endocrinol Metab Clin North Am       Date:  2017-12-18       Impact factor: 4.741

4.  Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia.

Authors:  J S Yudkin; R D Forrest; C A Jackson; A J Ryle; S Davie; B J Gould
Journal:  Diabetologia       Date:  1990-04       Impact factor: 10.122

5.  Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance.

Authors:  R R Little; J D England; H M Wiedmeyer; R W Madsen; D J Pettitt; W C Knowler; D E Goldstein
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

6.  Epidemiological features of glycated haemoglobin A1c-distribution in a healthy population. The Telecom Study.

Authors:  D Simon; C Senan; P Garnier; M Saint-Paul; L Papoz
Journal:  Diabetologia       Date:  1989-12       Impact factor: 10.122

7.  Relationships of cotinine and self-reported cigarette smoking with hemoglobin A1c in the U.S.: results from the National Health and Nutrition Examination Survey, 1999-2008.

Authors:  Carole Clair; Asaf Bitton; James B Meigs; Nancy A Rigotti
Journal:  Diabetes Care       Date:  2011-08-11       Impact factor: 19.112

8.  Cadmium exposure and incidence of diabetes mellitus--results from the Malmö Diet and Cancer study.

Authors:  Yan Borné; Björn Fagerberg; Margaretha Persson; Gerd Sallsten; Niklas Forsgard; Bo Hedblad; Lars Barregard; Gunnar Engström
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

9.  Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study.

Authors:  Esther van 't Riet; Marjan Alssema; Josina M Rijkelijkhuizen; Piet J Kostense; Giel Nijpels; Jacqueline M Dekker
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

10.  Cardiovascular disease, neuropathy, and retinopathy.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2009-06       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.